Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

The RV144 trial demonstrated 31% vaccine efficacy at preventing human immunodeficiency virus -1 infection.

http://www.citeulike.org/user/ammurira/article/11224374